The iShares US Pharmaceuticals ETF (IHE) is rated a hold due to fair valuation and increasing short-term challenges. Its portfolio is heavily concentrated, with 43% in Johnson & Johnson and Eli Lilly, and the top 10 holdings making up 76%. Technical indicators show weakening trends, including a recent break of trendline support, suggesting a possible 10% price correction to around $97 by October. Seasonal factors are also unfavorable in September and October, although long-term growth drivers like artificial intelligence remain promising. Investors should be cautious of near-term risks despite the ETF's strong summer performance.
Johnson & Johnson's recent quarterly report showed its MedTech segment sales fell short of Wall Street expectations, primarily due to pricing pressures in China and budget cuts in Europe. This shortfall caused the company's shares to decline, impacti...
Johnson & Johnson reported strong Q3 earnings with a 6% sales increase and raised its full-year guidance, yet its stock dropped nearly 6% after a weak MedTech segment performance and costs from recent acquisitions. Despite the selloff, key drug sales...
Johnson & Johnson reported resilient sales growth and exceeded earnings expectations, driven by promising results in its Innovative Medicine segment and potential growth from its MedTech OTTAVA system. However, softness in profitability and ongoing r...
Johnson & Johnson reported a 6% revenue increase to $25.4 billion in Q3 2026, but earnings per share (EPS) declined 7.5% year-on-year, causing the stock to fall 5%. The company set aside $5.5 billion to resolve talc litigation, aiming for 95% plainti...
Johnson & Johnson reported third-quarter 2026 earnings per share of $2.59, surpassing analyst estimates of $2.52, with total revenue of $25.40 billion slightly above expectations. The company saw robust growth in its pharmaceutical segment, which off...
